Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial

by Web Master, Benzinga Editor
January 22, 2013 6:00 PM | 5 seconds read |
New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!